Memorial Hospital Research Laboratories
The Luke Pike Lab
Research
The Luke Pike Lab seeks to understand the unique biology of brain metastasis (BrM) and to improve outcomes for patients afflicted with this terrible disease. BrM is an exceptionally common form of solid tumor metastasis, affecting approximately 400,000 U.S. cancer patients each year. The mechanisms by which cancer cells spread to and survive in the brain are poorly understood. A highly effective treatment for BrM is a form of radiation therapy called stereotactic radiosurgery. However, in recent years, new drugs have been developed with potential activity against BrM. The Pike Lab uses cutting-edge molecular techniques to understand tumor tropism for the brain and to identify features of human BM that might lead to drug or radiation resistance. We also seek to take these insights from the “bench to the bedside” through novel clinical trials and translational research studies that combine radiotherapy and new CNS-active drugs and identify biomarkers that may help guide therapeutic selection.
Publications Highlights
People
Luke Pike, MD, DPhil
- Physician-scientist Luke R.G. Pike studies the mechanistic underpinnings of brain metastasis and seeks to identify translational correlates with outcomes following local or systemic therapy.
- DPhil/PhD, Medical Oncology, University of Oxford
- MD, Yale School of Medicine
- [email protected]
- Email Address
- View physician profile
- Physician profile
Members
- PhD, Gerstner School of Graduate Sciences, Memorial Sloan Kettering
- MD, Weill Medical College, Cornell University (Tri-I MD-PhD)
Lab Alumni
Lab Affiliations
Achievements
- Alexander Graham Bell PhD Scholarship (2009)
- The Rhodes Scholarship (2007)
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Get in Touch
-
Lab Head Email
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Luke Pike discloses the following relationships and financial interests:
-
Dxcover Limited
Professional Services and Activities (Uncompensated) -
Genece Health, Inc.
Professional Services and Activities (Uncompensated)
-
Monograph Capital Advisors, L.P.
Professional Services and Activities
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].